Dutch life sciences venture capital firm Forbion has announced the hiring of Josh Brumm, former president and chief executive of Dyne Therapeutics, as a general partner. 1 July 2024
US biotech Arvinas has promoted Ian Taylor to president of R&D. Angela Cacace will take over from Dr Taylor in his current role of chief scientific officer. 18 June 2024
US gene therapy company Regenxbio has announced that co-founder Kenneth Mills is to step down as president and chief executive following 15 years of leadership 12 June 2024
I-Mab has appointed Phillip Dennis as chief medical officer, overseeing the company's global clinical development efforts and joining the executive leadership t 7 June 2024
Sapreme, a Dutch biotech developing next-generation RNA therapeutics for genetically-driven diseases, has appointed Marco Timmers as chief executive. 28 May 2024
SynaptixBio, a UK biotech that claims to be the world’s only company developing a therapy for TUBB4A-related leukodystrophies, has appointed Uwe Meya as chief m 23 May 2024
Boston-based genomic medicines company Ensoma has announced the appointment of Jim Burns as chief executive and a member of the board of directors. 13 May 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.